Physician profile

Michael Corbin

Psychiatry · Fort Lauderdale, FL

NPI 1548365463

$317.73

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$226.39

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Teva Pharmaceuticals USA, INC. $156.70 2024 Austedo Xr, Uzedy
Neurocrine Biosciences, INC. $56.26 2020-2024 Ingrezza
Otsuka America Pharmaceutical, INC. $38.64 2022-2024 Abilify Asimtufii, Abilify Maintena
Alkermes, INC. $20.47 2021
Janssen Pharmaceuticals, INC $18.07 2021
Supernus Pharmaceuticals, INC. $14.86 2024 Qelbree
Vanda Pharmaceuticals INC. $12.73 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Corbin

$317.73

in general payments reported 2019-2025

Years
2020-2024
Top company
Teva Pharmaceuticals USA, INC.

https://glasscript.com/doctor/251898/michael-corbin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.